PD 144795
PD 144795 is an orally active inhibitor of E-selectin (E-selectin), ICAM-1, and VCAM-1, with IC50 values of 6.6 μM, 4.0-10 μM, and 4.0 μM for the human targets, respectively. PD 144795 has favorable pharmacokinetic properties, including good absorption and no endothelial cytotoxicity. PD 144795 inhibits TNF-α-induced adhesion of neutrophils and monocytes to endothelial cells, reduces neutrophil infiltration, exudate accumulation, and footpad swelling, and delays disease progression in rodent models. PD 144795 can be used for inflammation-related research.
For research use only. We do not sell to patients.
- CAS No.: 148550-96-3
- Formula: C13H15NO4S
- Molecular Weight:281.33
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HUVEC | IC50 |
8.7 μM
|
Inhibition of TNF-α-stimulated neutrophil adhesion to human umbilical vein endothelial cells (HUVECs) measured via γ-ray spectroscopy after 4h incubation with TNF-α and 30min neutrophil incubation.
Inhibition of TNF-α-stimulated neutrophil adhesion to human umbilical vein endothelial cells (HUVECs) measured via γ-ray spectroscopy after 4h incubation with TNF-α and 30min neutrophil incubation.
|
jm00022a026 |
| HUVEC | IC50 |
4.0 μM
|
Inhibition of TNF-α-induced ICAM-1 surface expression on human umbilical vein endothelial cells (HUVECs) measured via ELISA after 30min pre-incubation with test compound followed by 4h TNF-α stimulation.
Inhibition of TNF-α-induced ICAM-1 surface expression on human umbilical vein endothelial cells (HUVECs) measured via ELISA after 30min pre-incubation with test compound followed by 4h TNF-α stimulation.
|
jm00022a026 |
| HUVEC | IC50 |
6.6 μM
|
Inhibition of TNF-α-induced E-selectin surface expression on human umbilical vein endothelial cells (HUVECs) measured via ELISA after 30min pre-incubation with test compound followed by 4h TNF-α stimulation.
Inhibition of TNF-α-induced E-selectin surface expression on human umbilical vein endothelial cells (HUVECs) measured via ELISA after 30min pre-incubation with test compound followed by 4h TNF-α stimulation.
|
jm00022a026 |
| HUVEC | IC50 |
5.7 μM
|
Inhibition of TNF-α-induced ICAM-1 surface expression on human umbilical vein endothelial cells (HUVECs) by the S-enantiomer of PD 144795 measured via ELISA.
Inhibition of TNF-α-induced ICAM-1 surface expression on human umbilical vein endothelial cells (HUVECs) by the S-enantiomer of PD 144795 measured via ELISA.
|
jm00022a026 |
| HUVEC | IC50 |
9.6 μM
|
Inhibition of TNF-α-induced E-selectin surface expression on human umbilical vein endothelial cells (HUVECs) by the S-enantiomer of PD 144795 measured via ELISA.
Inhibition of TNF-α-induced E-selectin surface expression on human umbilical vein endothelial cells (HUVECs) by the S-enantiomer of PD 144795 measured via ELISA.
|
jm00022a026 |
In Vitro
PD 144795 (incubated for 4 hours) inhibits TNF-α-stimulated adhesion of neutrophils to human umbilical vein endothelial cells with an IC50 of 8.7 μM[1].
PD 144795 (pretreatment for 30 minutes + incubation for 4 hours) inhibits TNF-α-induced expression of ICAM-1 and E-selectin on the surface of human umbilical vein endothelial cells, with IC50 values of 4.0 μM and 6.6 μM, respectively[1].
PD 144795 (overnight treatment) inhibits the adhesion of U937 monocytes to human aortic endothelial cells under TNF-α stimulation, with an IC50 of 8.8 μM[1].
PD 144795 (incubated for 18 h) inhibits TNF-α-induced expression of VCAM-1 and ICAM-1 on the surface of human aortic endothelial cells, with IC50 values of 4.0 μM and 10 μM, respectively[1].
PD 144795 modulates the expression of TNF-α-responsive genes in human umbilical vein endothelial cells and human aortic endothelial cells without inhibiting NF-κB activation[1].
PD 144795 (30-50 μM) showed no cytotoxicity in human aortic endothelial cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
PD 144795 (10 mg/kg; p.o.; single dose 1 hour prior to challenge) inhibits neutrophil accumulation by 68% and pleural exudate volume by 93% in a rat reverse passive Arthus pleurisy model[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c (female, inbred)[1]
-
Dosage:63 mg/kg (ID50)
-
Administration:p.o.
-
Result:Achieved an ID50 of 63 mg/kg for inhibiting neutrophil influx into the peritoneal cavity.
-
Animal Model:Wistar (male, outbred, 220-245 g)[1]
-
Dosage:10 mg/kg
-
Administration:p.o.; single dose 1 hour prior to challenge
-
Result:Inhibited neutrophil accumulation by 68%.
Inhibited pleural exudate volume by 93%.
Chemical Information
-
CAS No. 148550-96-3
-
Molecular Weight 281.33
-
Formula C13H15NO4S
-
SMILES
O=C(N)C1=C(OC(C)C)C=2C=C(OC)C=CC2S1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)